# Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

> **NCT03356782** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 20 (estimated)

## Conditions studied

- Sarcoma
- Osteoid Sarcoma
- Ewing Sarcoma

## Interventions

- **BIOLOGICAL:** Sarcoma-specific CAR-T cells

## Key facts

- **NCT ID:** NCT03356782
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356782, "Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03356782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*